Prostatype Genomics AB
ABActiveOrg 5567260285Augustendalsvägen 20, 131 52 Nacka StrandResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2007 · 19 years old1-4 employees
Loading company…
Overview
Prostatype Genomics AB is a Swedish AB based in Nacka Strand, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2007, the company reported revenue of SEK 199 in its latest annual filing.
Revenue 2024
0.2K SEK
−100% vs 2023
EBITDA margin
−18,424.1 %
+100% vs 2023
Net profit 2024
-41.1K SEK
+100% vs 2023
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
79.7 %
StrongAmong the 40% highest rated companies in the industry
20202024
Liquidity ratioCurrent assets ÷ Short-term debt
1.4×
WeakAmong the 30% lowest rated companies in the industry
20202024
Return on assets (ROA)Net profit ÷ Total assets × 100
-97.8 %
Very weakAmong the 10% lowest rated companies in the industry
20202024
EBITDA — year on year
SEK millionsKey figures
Annual report 2024| Revenue | 0.2K SEK | -100% |
| EBITDA | -36.7K SEK | +100% |
| Net profit | -41.1K SEK | +100% |
| Total assets | 42K SEK | -100% |
| Equity | 33.5K SEK | -100% |
| Employees | — | — |
Company information
Legal name
Prostatype Genomics AB
Org number
5567260285
Legal form
Aktiebolag
Founded
12 March 2007 · 19 years
Share capital
SEK 670
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Koch, Lars Anders Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget skall direkt eller indirekt bedriva forskning, utveckling och försäljning av medicintekniska produkter och läkemedel, äga och förvalta aktier och andra värdepapper, samt därmed förenlig verksamhet.
(no translation available)
Contact
Address
Augustendalsvägen 20, 131 52 Nacka Strand
Email
info@prostatypegenomics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2024), Prostatype Genomics AB reported revenue of SEK 199, a decrease of 100% on the year before. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a net loss of SEK 41.1k, and the EBITDA margin stood at -18,424.1%.
At the end of 2024, equity financed 79.7% of the balance sheet, and current assets covered short-term debt 1.4 times.
Financials
Revenue
SEK thousandsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 1,356 | 683 | 10 | 684 |
| Staff expenses | -16 | — | — | — | — |
| EBITDA | -37 | -30,970 | -26,786 | -15,460 | -15,765 |
| Depreciation & amort. | -2 | -1,875 | -1,904 | -88 | -149 |
| EBIT | -41 | -32,845 | -28,690 | -15,548 | -15,914 |
| Net financials | -2 | -2,356 | -396 | -81 | -1,494 |
| Profit before tax | -41 | -34,559 | -29,087 | -15,630 | -17,408 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -41 | -34,559 | -29,087 | -15,630 | -17,408 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | 42 | 55,584 | 30,950 | 40,203 | 33,663 |
| Equity | 33 | 31,196 | 26,151 | 35,906 | 28,290 |
| Long-term debt | 0 | 67 | 467 | 867 | 1,067 |
| Short-term debt | 9 | 24,321 | 4,333 | 3,430 | 4,306 |
| Total debt | 9 | 24,388 | 4,800 | 4,297 | 5,373 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20202024
Equity ratio
79.7 %
StrongAmong the 40% highest rated companies in the industry
20202024
Return on equity
-122.7 %
Very weakAmong the 10% lowest rated companies in the industry
20202024
Net profit margin
<−999 %
Very weakAmong the 10% lowest rated companies in the industry
20202024
Asset turnover
0.00×
WeakAmong the 30% lowest rated companies in the industry
20202024
Debt / equity
0.25×
StrongAmong the 40% highest rated companies in the industry
20202024
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 10% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery weak
Among the 10% lowest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery weak
Among the 10% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 10% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 40% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery strong
Among the 20% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalWeak
Among the 30% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioWeak
Among the 30% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioStrong
Among the 40% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioStrong
Among the 40% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityStrong
Among the 40% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityStrong
Among the 40% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 40% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverWeak
Among the 30% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverStrong
Among the 30% highest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalVery strong
Among the 20% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
LA External Signatory | External Signatory | 2024 |
KF Chief Executive Officer | Chief Executive Officer | 2020 |
JK Chief Auditor | Chief Auditor | 2022 |
Former (1)
LA Chief Auditor | Chief Auditor | 2020 – 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
BH Board of Directors | Board of Directors | 2020 |
MV Board of Directors | Board of Directors | 2022 |
JM Board of Directors | Board of Directors | 2020 |
AB Board of Directors | Board of Directors | 2020 |
SA Chairman | Chairman | 2020 |
CJ Board of Directors | Board of Directors | 2023 |
Former (5)
JF Board of Directors | Board of Directors | 2024 – 2025 |
CP Board of Directors | Board of Directors | 2020 – 2022 |
KS Board of Directors | Board of Directors | 2022 – 2023 |
CL Board of Directors | Board of Directors | 2020 – 2021 |
PH Board of Directors | Board of Directors | 2020 – 2023 |
Shareholders
Active legal ownersNo shareholder data available.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Prostatype Genomics AB (this company)
Prostatype Genomics Inc100% ownedProstatype Genomics Inc100% ownedBoard network connections
Board members of Prostatype Genomics AB also hold positions in 235 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Kjell Joakim Söderin | Chief Auditor | 122 companiesMany roles |
| Lars Anders Meyer | Chief Auditor | 73 companiesMany roles |
| Sven Anders Liljeblad | Chairman | 10 companiesMany roles |
| Bengt Håkan Englund | Board of Directors | 6 companiesMany roles |
| Mattias Viktor Prage | Board of Directors | 6 companiesMany roles |
| Anders Bo Folke Garibaldi Lundberg | Board of Directors | 6 companiesMany roles |
| Lars Anders Koch | External Signatory | 5 companies |
| Johan Fredrik Waldhe | Board of Directors | 3 companies |
| Jan Michael Häggman | Board of Directors | 2 companies |
| Karl Fredrik Rickman | Chief Executive Officer | 1 company |
| Carl Jörgen Dahlström | Board of Directors | 1 company |
Frequently asked questions
What is the Org number of Prostatype Genomics AB?
Prostatype Genomics AB is registered with Bolagsverket / SCB under Org 5567260285.
What is the revenue of Prostatype Genomics AB?
Prostatype Genomics AB reported revenue of SEK 199 in 2024.
Who is the CEO of Prostatype Genomics AB?
Karl Fredrik Rickman is the CEO of Prostatype Genomics AB, in role since 2020.
Who is the chairman of Prostatype Genomics AB?
Sven Anders Liljeblad chairs the board of Prostatype Genomics AB, in role since 2020.
Where is Prostatype Genomics AB headquartered?
Prostatype Genomics AB's registered address is Augustendalsvägen 20.